Business
Biomea Fusion Reports Third Quarter 2022 Financial Results and Business Highlights
Continued to establish Biomea Fusion as the next-generation leader in covalent medicinesExpanded clinical development footprint of BMF-219, the company’s lead
About this update from Biomea Fusion, Inc.
[{"type":"text","content":"Continued to establish Biomea Fusion as the next-generation leader in covalent medicinesExpanded clinical development footprint of BMF-219, the company’s lead investigational, orally administered, covalent menin inhibitor, in multiple liquid and solid tumor indications, including first in class potential in KRAS-mutated solid tumors COVALENT-101 (Phase I study) is now enrolling four liquid tumor cohorts, each focused on distinct patient subsets of acute lymphoblastic and myeloid leukemia (ALL/AML) including patients with MLL rearrangement and NPM1 mutation, diffuse large B-cell lymphoma (DLBCL), multiple myeloma (MM) and most recently chronic lymphocytic leukemia (CLL)COVALENT-102 (Phase I/Ib study) is now enrolling patients with KRAS-mutated (pan) solid tumors, including non-small cell lung cancer (NSCLC), colorectal cancer (CRC) and pancreatic ductal adenocarcinoma (PDAC)COVALENT-111 (Phase I/II study) advanced BMF-219 to the clinic for type 2 diabetes indication; cleared the Phase I healthy volunteer portion of this study in Canada and dosed first patient with type 2 diabetes Continued to advance company’s second product candidate, BMF-500, a highly selective and potent covalent third generation FLT3 inhibitor, toward the clinicContinued to leverage the proprietary FUSIONTM System Discovery Platform to expand pipeline of covalent medicines for cancer; expect to provide an update on company’s third development candidate in the first half of 2023Cash position of $133.8 million at the end of the third quarter of 2022 REDWOOD CITY, Calif., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing novel covalent small molecules to treat and improve the lives of patients with genetically defined cancers and metabolic diseases, reported third quarter 2022 financial results and business highlights. “We continue to solidify Biomea’s position as the leader in next-generation covalent medicines, and build near- and long-term value, through our rapid progress and strong execution. With BMF-219, we have now brought the first covalent menin inhibitor to the clinic for KRAS-mutated solid tumors, adding to our already robust development strategy of BMF-219 in distinct patient subsets of multiple liquid tumors. In addition, we are very excited to an...